Vertex Hepatitis Drug Beats Forecasts

Vertex Pharmaceuticals is off to a running start with its new hepatitis C drug. The Cambridge company said had it generated $74.5 million in sales of telaprevir in the quarter that ended June 30.
Boston Globe